Suzhou Xinmaide
Solomons-China security
About Suzhou Xinmaide
Founded in 2016, SINGMED specializes in the design, research and development, and manufacturing of advanced drug delivery devices. The company focuses on creating drug-device combination products, particularly Dry Powder Inhalers (DPI), which are widely used for treating asthma and chronic obstructive pulmonary disease (COPD). DPIs offer several advantages, including portability, ease of use, quick administration, and minimal throat irritation, making them a preferred choice for many patients.
SINGMED serves a diverse client base, including pharmaceutical companies and healthcare providers, operating primarily in the medical device and pharmaceutical markets. The company's business model revolves around the development and sale of its proprietary drug delivery devices, as well as partnerships and collaborations with other pharmaceutical firms to create combination products. Revenue is generated through the sale of these devices and products, as well as through licensing agreements and royalties.
SINGMED's commitment to innovation and quality is evident in its continuous investment in research and development, as well as its recent expansion with the completion of the Singmed Changshu Production Base. This new facility marks a significant milestone in the company's growth and underscores its dedication to advancing medical technology.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Suzhou Shi, China
- Open positions
- None listed
- Dealroom signal
- 18.3/100
- Industry
- Security
- Sector
- Cybersecurity
- Business model
- SaaS
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Apr 2026 | $41M | $165M | UOB Venture · Jinyu Maowu Investment · Changshu Guofa Venture Capital · Hongyuan Capital | ↗ |
| SERIES B✓Equity / VC | Jan 2026 | $0 | — | Oriza Holdings · SIBIONICS · Hongyuan Capital | ↗ |
Growth signals
Latest recorded traffic for Suzhou Xinmaide is 1.9K monthly website visits, up 175.4% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Suzhou Xinmaide in the Suzhou Shi ecosystem
The Suzhou Xinmaide office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
- HCHongyuan Capital
Oriza Holdings
SIBIONICS
UOB Venture- JIJinyu Maowu Investment
- CCChangshu Guofa Venture Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Suzhou Xinmaide on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Suzhou Xinmaide’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








